3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological products, has installed a new 500-liter stainless steel fermenter to complement its existing capacity for protein production from bacteria and yeast with fermentation technology.

The addition of this new capacity complements the existing three fermentation lines that carry out drug production from bacteria and yeast. This means that 3P Biopharmaceuticals now has availability of 10 L, 100L, 500L, and 1,000 L capacities for microbial manufacturing.

The new fermenter, which complies with the regulatory standards of Good Manufacturing Practices (GMPs) of the European Medicines Agency (EMA), will allow the Navarran biotech company to multiply by five the production capacity of one of its three microbial manufacturing lines.

“The demand for microbial protein manufacturing capacity is increasing nowadays and customers require more capacity for their projects,” said Dámaso Molero, CEO of 3P Biopharmaceuticals. “At 3P we will always be ready to adapt to meet all of their needs.”

Elena Erroba, business development director at 3P, said, “3P has a proven and established reputation as a leading CDMO in the manufacture of biologic medicines with microbial technology and the expansion of our capacity with this new 500 L fermenter allows us to support new and existing customers in the clinical development and commercial supply of their therapies.”

With the recent renovations that 3P has carried out over the last 3 years, its facilities now total 10,500 square meters. The main purpose of the remodelling is to further expand its production capacity and increase the efficiency of its process development and manufacturing services.